<DOC>
	<DOCNO>NCT00867139</DOCNO>
	<brief_summary>The purpose study assess safety tolerability triple combination antiviral drug ( TCAD ) use immunocompromised patient Influenza A infection , gain data effectiveness TCAD</brief_summary>
	<brief_title>TCAD vs. Monotherapy Influenza A Immunocompromised Patients</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<mesh_term>Zanamivir</mesh_term>
	<mesh_term>Thiazole-4-carboxamide adenine dinucleotide</mesh_term>
	<criteria>. Inclusion criterion randomize arm ( need ) : 1 . Age ≥7 year , male female ; AND 2 . Influenza infection ( i.e . upper respiratory tract infection ) ii . Inclusion criterion openlabel arm ( least one criterion require ) : 1 . Young age ( 16 year ) influenza severity , proven probable influenza A ( H1N1 ) ( H274Y ) ; OR 2 . History asthma ; OR 3 . Older age ( ≥ 7 year ) , asthma ; AND moderate severe influenza ; AND/OR failure randomize study monotherapy arm iii . Inclusion criteria subject : 1 . Able provide inform consent , consent may provide guardian 2 . Immunocompromised , define one following : Recent hematopoietic cell transplantation ( HCT ) ( within 2 year , conditioning regimen , allogeneic , autologous , syngeneic ; 2 year patient chronic graftversushost disease ( GVHD ) require systemic treatment may include ) solid organ transplantation Patients take least 2 immunosuppressant Patients undergoing combination chemotherapy within past 3 month 3 . One following : Presence fever time screen ≥ 38.0°C ( ≥ 100.0°F ) take orally . presence least one constitutional symptom ( headache , myalgia , malaise , fatigue ) severity ( mild , moderate , severe ) , presence least one respiratory symptom ( e.g . cough , sore throat ) severity ( mild , moderate , severe ) , flulike symptom , clinician order respiratory virus test include influenza A B 4 . Positive test influenza A ( available ) 5 . Onset illness 5 day prior diagnosis . 6 . Females patient childbearing age capable conception ( i.e . previously undergone surgical sterilization ) must meet following criterion : Have sexually abstinent use contraceptive agent ( oral contraceptive hormonal contraceptive include vaginal ring transdermal patch , intrauterine device ( IUD ) , barrier method include condom ) 4 week prior date screening ( 3 month prior enrollment oral/hormonal contraceptive ) Agree sexually abstinent use contraceptive agent ( oral contraceptive hormonal contraceptive include vaginal ring transdermal patch , intrauterine device ( IUD ) , barrier method include condom ) date screen 24 week last dose study drug Exclusion Criteria ( subject ) : 1 . Nausea prevents take oral medication 2 . Use antiviral influenza medication within 10 day ( unless switch randomize openlabel TCAD ) . An exception exclusion criterion may make site investigator patient admitted hour receive one two initial dos antiviral influenza medication prior enrollment . 3 . Creatinine clearance ( estimate serum creatinine ) less 30 ml/min 4 . Current clinical evidence recognize suspect uncontrolled noninfluenza infectious illness onset prior screen 5 . Known hypersensitivity amantadine , ribavirin , oseltamivir zanamivir 6 . Women pregnant ( positive serum urine pregnancy test ) , attempt become pregnant , breastfeed 7 . Psychiatric cognitive illness , recreational drug/alcohol use , opinion principal investigator , would affect patient safety and/or compliance 8 . Uncontrolled seizure disorder history seizure activity within 12 month prior study participation 9 . Any significant finding patient 's medical history physical exam Day 1 , opinion investigator , would affect patient safety compliance dose schedule 10 . Documented Influenza B viral coinfection</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Immunocompromised</keyword>
	<keyword>Antiviral</keyword>
</DOC>